Darzalex (daratumumab) 100mg/5ml Injection

Description

Darzalex (daratumumab) is a monoclonal antibody used to treat multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. Darzalex is designed to target a protein called CD38, which is present on the surface of myeloma cells. By binding to CD38, Darzalex helps to destroy cancer cells and slow the progression of the disease.

Uses
Darzalex is approved by the US Food and Drug Administration (FDA) for the treatment of multiple myeloma in several settings. The drug may be used alone or in combination with other medications, such as lenalidomide and dexamethasone, in patients who have received at least one previous therapy. Darzalex may also be used in combination with bortezomib, melphalan, and prednisone for the treatment of newly diagnosed multiple myeloma in patients who are not eligible for autologous stem cell transplant.

How It Works
Darzalex is a monoclonal antibody that targets CD38, a protein that is heavily expressed on the surface of myeloma cells. By binding to CD38, Darzalex depletes the number of myeloma cells and may also enhance the immune system’s ability to recognize and attack cancer cells. The drug is given intravenously and is typically administered over several hours.